ClinicalTrials.gg
Status unknownNCT02977364Updated Nov 30, 2016

A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours

A Phase 1 interventional study of HS-10241 in Carcinoma and Solid Tumor, Adult, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-30.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies in Carcinoma with a site in China — 37 open to participants now, 49 under way, 12 of them phase 3. Carcinoma · China.

Planned enrollment
50th of 82
50 · median 72
Started
2016
with 2 others
Phase 1
12 of 101
6 open now
Registered
26th of 101
by date

Among the 101 studies in Carcinoma with a site in China, this one is the 50th largest by planned enrollment of the 82 interventional ones that give a count, is one of 3 that started in 2016, is one of 12 in phase 1, and was the 26th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

37 of the 101 studies in Carcinoma with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Carcinoma with a site in China, or all of them as a file.
02

Study summary

To investigate safety, tolerability and pharmacokinetics of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours that are not eligible for conventional or intensive treatment. The dose of HS-10241 will be escalated to determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) of HS-10241 in advanced cancer patients. At the same time, pharmacokinetic characteristics and preliminary efficacy of HS-10241 will be observed in advanced cancer patients. To determine the recommended dosage regimen for phase II.

03

Conditions studied

  • Carcinoma
  • Solid Tumor, Adult

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed advanced or solid tumor for which standard therapy does not exist, has failed, or has been refused.
  2. c-MET positive patients preferred in dose escalation phase; c-MET of patients must fulfill ICH++\~+++ or FISH≥4 times in dose expansion phase.
  3. Confirmed that there are at least 1 can be measured in accordance with the standard RECIST1.1 by CT or MRI.
  4. 18 \~65 years of age.
  5. performance status of 0\~1.
  6. of at least 3 months.
  7. Recovered from toxicities of prior anti-cancer treatment to Grade 1 or less (except alopecia).
  8. Acceptable hematologic status (without hematologic supports including hematopoietic factor, blood transfusion) defined below:

    • (ANC) ≥ 1500/μL
    • count ≥ 100000/μL
    • ≥ 9.0 g/dL
  9. Acceptable liver function defined below:

    • Total ≤ 2 times (ULN)
    • (AST) and alanine aminotransferase (ALT) ≤ 3 times ULN; however, ≤ 5 times ULN in a subject who has liver metastases
  10. Acceptable renal function defined below:

    • Serum creatinine ≤ 1.5 times ULN or calculated (by the Cockcroft-Gault formula) ≥ 60 mL/minutes
  11. Acceptable coagulation status defined below:

    • \< 1.5 times ULN
    • Partial thrombin time \< 1.5 times UL
  12. Ag/Ab(-).
  13. Ab(-);or HCV Ab(+) but HCV RNA(-).
  14. (-)and HBcAb(-)in dose escalation phase;HBV DNA\<1×103copies/ml if HBsAg(+)or HBcAb(+)in dose expansion phase.
  15. Ability to understand the purposes and risks of the trial and his/her using the human research ethics committee (HREC) approved informed consent form was obtained before the entering the trial.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with other c-MET TKI( specific target or multi-target);
  2. Anti-cancer treatment with radiation therapy(not including non target lesions receiving palliative radiotherapy), chemotherapy,hormonotherapy or surgery(small surgery, including the implantation of external equipment or fine needle aspiration, at least 7 days; diagnostic or palliative surgery, at least 14 days) within 4 weeks (6 weeks for nitrosoureas or Mitomycin C)prior to trial entry.
  3. Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product
  4. Cardiac disease with (NYHA) Class III or IV, including congestive heart failure, myocardial infarction within 6 months prior to the trial entry, unstable arrhythmia, or symptomatic peripheral arterial vascular disease.
  5. Symptomatic or unstable brain metastases (notes: Patients with asymptomatic brain metastases previously treated for the study, but must be kept stable for at least 4 weeks and receive a stable dose of the drug)
  6. Obvious neurological and mental disorder.
  7. Other previous or concomitant tumors (except for the effective treatment of melanoma, cervical carcinoma in situ, ductal carcinoma in situ or malignant tumor after effective treatment, remission 3 years and considered to have been cured).
  8. Active, uncontrolled bacterial, fungal infections, requiring systemic therapy.
  9. Recent venous thrombosis (including deep vein thrombosis or pulmonary embolism within 0.5 year of trial entry)
  10. History of organ allograft, stem cell transplantation, or allogeneic stem cell transplantation.
  11. Participation in an drug or device trial within 4 weeks prior to the trial entry.
  12. Anti-cancer treatment with radiation therapy, chemotherapy or immunotherapy within 4 weeks (6 weeks for nitrosoureas or Mitomycin C) prior to trial entry.
  13. Major surgery, other than diagnostic surgery, within 4 weeks prior to the trial entry, without complete recovery
  14. Taking a medication that is a moderate or strong inhibitor or inducer of CYP2C9; taking a medication that prolongs and has a risk of Torsades de Pointes .
  15. Pregnant (positive serum beta human chorionic gonadotropin [β-HCG] test at Screening) or is currently breast-feeding, their partner anticipates becoming pregnant/impregnating during the trial or within 6 months after receiving the last dose of trial treatment.
  16. Known drug abuse or alcohol abuse.
  17. Concomitant disease or condition that could interfere with the conduct of the trial, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    HS-10241 100mg

    HS-10241 100mg daily

    Drug: HS-10241

  • Experimental
    HS-10241 200mg

    HS-10241 200mg daily

    Drug: HS-10241

  • Experimental
    HS-10241 400mg

    HS-10241 400mg daily

    Drug: HS-10241

  • Experimental
    HS-10241 600mg

    HS-10241 600mg daily

    Drug: HS-10241

  • Experimental
    HS-10241 800mg

    HS-10241 800mg daily

    Drug: HS-10241

  • Experimental
    HS-10241 1000mg

    HS-10241 1000mg daily

    Drug: HS-10241

Interventions

06

What researchers measure

Primary outcomes

  1. MTD of HS-10241 based on the incidence of dose limiting toxicities

    Time frame: 4 weeks

Secondary outcomes

  1. Progression-free survival (PFS)

    Time frame: 12 months

  2. Max concentration (Cmax) of HS-10241

    Time frame: 4 weeks

  3. Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1

    Time frame: 8 weeks

  4. Incidence and intensity of Adverse Events according to Common Toxicity Criteria for AEs (CTCAE version 4.0)

    Time frame: 8 weeks

  5. Area under the plasma concentration versus time curve (AUC) of HS-10241

    Time frame: 4 weeks

  6. Elimination half-life(T1/2) of HS-10241

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2016, a primary completion of Nov 2018 and a completion of Nov 2021. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2016
First posted
Nov 30, 2016
Start
Nov 2016
Primary completionEst.
Nov 2018
CompletionEst.
Nov 2021
Last update
Nov 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02977364
Responsible party
Sponsor
First posted
Nov 30, 2016
Start date
Nov 2016
Primary completion
Nov 2018 (estimated)
Completion
Nov 2021 (estimated)
Last update
Nov 30, 2016

Study contacts

Yuankai Shi, MD
Contact
syuankaipumc@126.com
86(10)87788293

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: C-Met Inhibitor HS-10241

Start the discussion